Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). However, their efficacy and safety in patients with idiopathic interstitial pneumonias (IIPs) or interstitial lung abnormalities (ILAs) remain poorly defined, as such patients have been largely excluded from pivotal clinical trials. This study aimed to assess real-world outcomes and adverse events associated with ICI-based therapies in patients with NSCLC and coexisting IIPs or ILAs.

Methods

We conducted a multicenter retrospective cohort study across 11 institutions affiliated with the North Japan Lung Cancer Study Group. Patients with advanced NSCLC and pre-existing IIPs or ILAs who received ICI monotherapy or ICI plus chemotherapy (chemo

SUBMITTER: Okumura F 

PROVIDER: S-EPMC12683449 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature